文献速递免疫规划传染病防控与疫情报告

香港2020至2022年Comirnaty或CoronaVac接种者、感染者及突破感染者血清对SARS-CoV-2奥密克戎BA.2变异株的中和反应

SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
PubMed 文献 · Euro Surveill · 2022-01-01

该研究用50%蚀斑减少中和试验检测Comirnaty或CoronaVac接种者、既往野生型SARS-CoV-2感染者及突破感染者血清对BA.2等变异株的中和抗体滴度。BA.2与BA.1滴度相当但显著低于野生型;三剂Comirnaty或异源加强后多数人产生可检测BA.2抗体,三剂CoronaVac者较少;BA.1或BA.2突破感染者具有广谱交叉中和抗体。

要点

  • BA.2与BA.1的PRNT50滴度相当,但均显著低于野生型SARS-CoV-2(p<10^-5)。
  • 三剂Comirnaty、两剂CoronaVac加一剂Comirnaty或感染后一剂疫苗者中,每组20人至少19人BA.2滴度≥10。
  • 三剂CoronaVac接种者20人中仅15人BA.2滴度≥10;BA.1或BA.2突破感染者有广谱交叉中和抗体。

核心结论

  • 现有疫苗对BA.2亚变异株可有帮助。

研究设计与样本

  • 采用50%蚀斑减少中和试验(PRNT50)评估Comirnaty或CoronaVac接种者(有或无既往野生型SARS-CoV-2感染)及非接种康复者血清中对BA.2、野生型SARS-CoV-2和其他变异株的中和抗体滴度。
  • 另研究BA.2和BA.1突破感染者及非接种者BA.2感染的中和抗体。

主要发现

  • 在接种者或既往野生型SARS-CoV-2感染者中,BA.2和BA.1的PRNT50滴度相当,但显著低于野生型(p<10^-5)。
  • 每组20名接种者中,三剂Comirnaty组、两剂CoronaVac后一剂Comirnaty组、或野生型感染后一剂任一疫苗组,至少19人产生可检测BA.2抗体(PRNT50滴度≥10),而三剂CoronaVac接种组20人中仅15人。
  • Comirnaty接种诱导的BA.2滴度高于CoronaVac。
  • 在野生型SARS-CoV-2感染康复者中,单剂疫苗诱导的BA.2滴度高于未感染个体接种三剂Comirnaty(p=0.02)或三剂CoronaVac(p=0.00001)。
  • 既往未感染且未接种者BA.2感染引发低应答(PRNT50滴度≤80),对其他变异株交叉中和很少;而BA.1或BA.2突破感染的接种者对野生型、BA.1、BA.2、Beta和Delta变异株有广谱交叉中和抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundOmicron subvariant BA.2 circulation is rapidly increasing globally.AimWe evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants.MethodsUsing 50% plaque reduction neutralisation tests (PRNT50), we assessed neutralising antibody titres to BA.2, wild type (WT) SARS-CoV-2 and other variants in Comirnaty or CoronaVac vaccinees, with or without prior WT-SARS-CoV-2 infection. Titres were also measured for non-vaccinees convalescing from a WT-SARS-CoV-2 infection. Neutralising antibodies in BA.2 and BA.1 breakthrough infections and in BA.2 infections affecting non-vaccinees were additionally studied.ResultsIn vaccinees or prior WT-SARS-CoV-2-infected people, BA.2 and BA.1 PRNT50 titres were comparable but significantly (p < 10 - 5) lower than WT. In each group of 20 vaccinees with (i) three-doses of Comirnaty, (ii) two CoronaVac followed by one Comirnaty dose, or (iii) one dose of either vaccine after a WT-SARS-CoV-2 infection, ≥ 19 individuals developed detectable (PRNT50 titre ≥ 10) antibodies to BA.2, while only 15 of 20 vaccinated with three doses of CoronaVac did. Comirnaty vaccination elicited higher titres to BA.2 than CoronaVac. In people convalescing from a WT-SARS-CoV-2 infection, a single vaccine dose induced higher BA.2 titres than three Comirnaty (p = 0.02) or CoronaVac (p = 0.00001) doses in infection-naïve individuals. BA.2 infections in previously uninfected and unvaccinated individuals elicited low (PRNT50 titre ≤ 80) responses with little cross-neutralisation of other variants. However, vaccinees with BA.1 or BA.2 breakthrough infections had broad cross-neutralising antibodies to WT viruses, and BA.1, BA.2, Beta and Delta variants.ConclusionsExisting vaccines can be of help against the BA.2 subvariant.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Cheng SM, Mok CKP, Chan KC, et al. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Euro Surveill. 2022. PMID: 35514306. doi:10.2807/1560-7917.ES.2022.27.18.2200178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。